Subcutaneous immunoglobulins in chronic lymphocytic leukemia with secondary antibody deficiency. A monocentric experience during Covid-19 pandemics
© 2022 John Wiley & Sons Ltd..
Secondary antibody deficiency (SAD) is a frequent manifestation of chronic lymphocytic leukemia (CLL) that increases the risk of infections. However, no formal guideline are available regarding the eligibility for prophylaxis or the delivery method, dosage, frequency of administration and duration of immunoglobulin replacement therapy (IgRT). The aim of this study was to assess the efficacy and safety of subcutaneous IgRT (SCIg) and its impact on quality of life (QoL) of CLL pts in the Covid-19 era. Ten CLL pts with SAD were treated with subcutaneous IgRT (SCIg) at our institution between October 2019 and December 2020. Median age was 66 years and five patients had comorbidities. Seven patients were receiving therapy for CLL when treatment with SCIg was initiated. All pts received 10 g total dose hyaluronidase-free SCIg independently from body weight. The IgG level and CD4/CD8, CD19 and CD16/56 lymphocytes subset were recorded at baseline and every 3 months. No patient experienced infectious events nor Covid-19 mediated interstitial pneumonia while on SCIg therapy. All patients tolerated well the therapy and experienced an increase of IgG levels, which was then stable in time. We conclude that SCIg administration in CLL pts with SAD is efficacious and safe as infectious prophylaxis. This route of administration appears particularly advantageous in the Covid-19 era, because of the self-administration at home which results in improvement in the QoL and reduced treatment expenditures.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Hematological oncology - 40(2022), 3 vom: 01. Aug., Seite 469-474 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Innocenti, Idanna [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chronic lymphocytic leukemia |
|---|
| Anmerkungen: |
Date Completed 09.08.2022 Date Revised 05.10.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/hon.2966 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM336106165 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM336106165 | ||
| 003 | DE-627 | ||
| 005 | 20231225231400.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/hon.2966 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1120.xml |
| 035 | |a (DE-627)NLM336106165 | ||
| 035 | |a (NLM)35076123 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Innocenti, Idanna |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Subcutaneous immunoglobulins in chronic lymphocytic leukemia with secondary antibody deficiency. A monocentric experience during Covid-19 pandemics |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.08.2022 | ||
| 500 | |a Date Revised 05.10.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 John Wiley & Sons Ltd. | ||
| 520 | |a Secondary antibody deficiency (SAD) is a frequent manifestation of chronic lymphocytic leukemia (CLL) that increases the risk of infections. However, no formal guideline are available regarding the eligibility for prophylaxis or the delivery method, dosage, frequency of administration and duration of immunoglobulin replacement therapy (IgRT). The aim of this study was to assess the efficacy and safety of subcutaneous IgRT (SCIg) and its impact on quality of life (QoL) of CLL pts in the Covid-19 era. Ten CLL pts with SAD were treated with subcutaneous IgRT (SCIg) at our institution between October 2019 and December 2020. Median age was 66 years and five patients had comorbidities. Seven patients were receiving therapy for CLL when treatment with SCIg was initiated. All pts received 10 g total dose hyaluronidase-free SCIg independently from body weight. The IgG level and CD4/CD8, CD19 and CD16/56 lymphocytes subset were recorded at baseline and every 3 months. No patient experienced infectious events nor Covid-19 mediated interstitial pneumonia while on SCIg therapy. All patients tolerated well the therapy and experienced an increase of IgG levels, which was then stable in time. We conclude that SCIg administration in CLL pts with SAD is efficacious and safe as infectious prophylaxis. This route of administration appears particularly advantageous in the Covid-19 era, because of the self-administration at home which results in improvement in the QoL and reduced treatment expenditures | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Covid 19 | |
| 650 | 4 | |a chronic lymphocytic leukemia | |
| 650 | 4 | |a hypogammaglobinemia | |
| 650 | 4 | |a immune dysfunction | |
| 650 | 4 | |a infections | |
| 650 | 4 | |a subcutaneous immunoglobulins | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 700 | 1 | |a Tomasso, Annamaria |e verfasserin |4 aut | |
| 700 | 1 | |a Benintende, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Autore, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Fresa, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Vuono, Florenzia |e verfasserin |4 aut | |
| 700 | 1 | |a Stirparo, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Galli, Eugenio |e verfasserin |4 aut | |
| 700 | 1 | |a D'Arena, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Sorà, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Efremov, Dimitar |e verfasserin |4 aut | |
| 700 | 1 | |a Laurenti, Luca |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hematological oncology |d 1993 |g 40(2022), 3 vom: 01. Aug., Seite 469-474 |w (DE-627)NLM012648280 |x 1099-1069 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2022 |g number:3 |g day:01 |g month:08 |g pages:469-474 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/hon.2966 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2022 |e 3 |b 01 |c 08 |h 469-474 | ||